Cumberland Pharmaceuticals vs Lexicon Pharmaceuticals
CPIX and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CPIX and LXRX compare
Lexicon Pharmaceuticals is the larger company, worth 9.0 times as much as Cumberland Pharmaceuticals ($796M against $88.1M).
Cumberland Pharmaceuticals grew revenue faster over the last twelve months (10.7% versus −45.6% for Lexicon Pharmaceuticals).
Cumberland Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 274% compared with −162% at Lexicon Pharmaceuticals.
Cumberland Pharmaceuticals pays a dividend yielding 25.5%; Lexicon Pharmaceuticals does not pay one.
Cumberland Pharmaceuticals scores higher on the StockData Score (10 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CPIX | LXRX |
|---|---|---|
| Size and price | ||
| Market cap | $88.1M | $796M |
| Share price | $5.88 | $1.79 |
| Change, 1 year | 175% | 16.2% |
| Change, 5 years | 136% | −63.9% |
| Beta (5Y) | 0.29 | 1.76 |
| Employees | 93 | 81 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 2 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 1.3× | – |
| P/S | 3.5× (better) | 20.7× |
| P/B | 1.2× (better) | 4.9× |
| FCF yield | −1.1% | – |
| Fair value | – | $0.871 |
| Margin of safety | – | −106% |
| Growth | ||
| Revenue growth (TTM) | 10.7% (better) | −45.6% |
| Revenue growth, 5Y average | 3.5% | 15.7% (better) |
| Profitability | ||
| Gross margin | – | 98.9% |
| Operating margin | −38.2% (better) | −147% |
| Net margin | 274% (better) | −162% |
| FCF margin | −3.9% | – |
| Return on equity | 140% (better) | −43.9% |
| Return on invested capital | −532% | −140% (better) |
| Financial health | ||
| Debt / equity | – | 0.32 |
| Interest coverage | −16.5× | – |
| Current ratio | 3.05 | 10.63 (better) |
| Altman Z-score | 2.21 (better) | −5.60 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 25.5% | – |
| Buyback yield | 0.36% (better) | −8.9% |
| Shareholder yield | 25.9% (better) | −8.9% |
| Ownership | ||
| Held by institutions | 16.5% | 81.9% |
| Held by insiders | 80.2% | – |
| Insider net buying, 12 months | – | $2.8M |
| Short interest, % of float | 10.1% | – |
Go deeper
- CPIX stock overview
- CPIX income statement
- CPIX valuation and score
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.